3 results
Approved WMOCompleted
The objective of this study is to determine the efficacy, safety, and tolerability of tafamidis in subjects with transthyretin cardiomyopathy.The primary objective is to assess the efficacy, safety, and tolerability of an oral dose of 20 mg or 80 mg…
Approved WMOCompleted
To evaluate the effect of the balance assisting device *GyBAR* on balance capacity during standing and gait tasks in people with pure degenerative ataxia.
Approved WMOCompleted
To obtain additional, long term, safety data for tafamidis in subjects with transthyretin amyloid cardiomyopathy (ATTR CM). To provide investigational product, tafamidis, to ATTR CM subjects who complete 30 months of blinded treatment on protocol…